START trial provides definitive evidence of the benefits of early HIV treatment
Innovative approaches to linkage to care boost clinic visits, HIV treatment uptake in African study
Non-daily PrEP regimens provide extra options, but adherence is often better with daily dosing
Targets proliferate in HIV cure research
No HIV infections from partners with fully suppressed viral load during long-term follow up of landmark treatment as prevention trial
Young woman stays undetectable for twelve years off treatment after early HIV therapy
Presumptive treatment of TB in advanced HIV no better than giving ART and isoniazid
Access to screening and treatment are key issues for hepatitis B and C and HIV/viral hepatitis co-infection
Vancouver Consensus Statement calls for early access to treatment and PrEP worldwide
